Kimberly Irvine, CIP, CIM

Articles by Kimberly Irvine, CIP, CIM

Playing in the Sandbox--How Local Institutional Review Boards Can Happily Co-Exist with Central IRBs

July 9th 2013

A recent paper published in PLOS ONE addresses research institutions? willingness ?or lack thereof?to defer to central institutional review boards for multicenter clinical trials.

Can a Central IRB Improve Efficiency?

ByKimberly Irvine, CIP, CIM

November 15th 2012

Academic Medical Centers as Study Sites: Tips for Success

ByKimberly Irvine, CIP, CIM

March 7th 2011

Latest Updated Articles

Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials
Published: February 13th 2025 | Updated: March 4th 2025
Accelerate Inclusive Enrollment and Delivery with Lightship
Published: February 19th 2025 | Updated: February 26th 2025
Examining the Impact of Exclusionary Behaviors on Team Dynamics
Published: March 24th 2023 | Updated:
Trials and Tribulations of Electronic Patient Consent: Removing Barriers to eConsent Adoption
Published: April 28th 2021 | Updated:
Sticking to the Plan: Undue Burden Created by Protocol Deviations
Published: July 26th 2024 | Updated:
Phase III PERSEUS Trial Data Show Darzalex Faspro Combo Improves Survival in Newly Diagnosed Multiple Myeloma
Published: January 31st 2024 | Updated:

Trending on Applied Clinical Trials Online

Driving Transformation With a Connected Clinical Platform: 2025 Veeva R&D and Quality Summit Clinical Opening Keynote

AstraZeneca’s Baxdrostat Shows Promise in Phase III Trial for Hard-to-Control Hypertension

Epkinly Demonstrates Encouraging Efficacy in Phase II Trial for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Promising Trial Data Leads to Breakthrough Designation for Eli Lilly’s Investigational KRAS G12C Inhibitor in Advanced, Metastatic Non-Small Cell Lung Cancer